MX3 to invest on research

-A A +A

Wednesday, August 27, 2014

DMI Medical Supply Co. Inc., (DMI), developer and distributor of food supplement MX3, will embark more on research and development to ensure highest and best quality products.

DMI Consultant Dr. Melanie G. Arcillas, during the company's press conference on Tuesday at the Capernaum, Southern Philippines Medical Center, said the company will take this initiative to respond to the needs of their market for high quality products.

She said they will tap the best research and clinical laboratories to help with the research and development of their product.


Arcillas did not disclose how much is allocated for research.

"I know very well that going into research or clinical studies is not cheap, we are talking about foreign laboratories here. Percentage wise maybe 30 percent will go to research but if you include development it will be around 50 percent," Arcillas said.

She added that "investing more for the quality of the product is like investing in life because we are talking about people taking the product. It is our [responsibility] before men [to provide with a product that has the best quality]."

Arcillas also said through research and clinical studies, they will be able to find out and determine more good benefits of their products.

Recent analysis, studies, and research include those from Canadian-based Nutrasource Diagnostics Inc. and US-based research provider Nutra Clinical Inc.

Nutrasource Diagnostics Inc. did an analysis of Xanthone content found in the MX3 500 mg capsule. Result of analysis indicated 39.4 mg of Mangostin-Alpha, Beta, Gamma found in the MX3 500mg capsule. The result surpassed the requirement of the International Standards for Xanthone Content in Food Supplement which is only 35 mg. Nutrasource Diagnostics Inc. released the Certificate of Analysis last month.

US-based research provider Nutra Clinical Inc. conducted a clinical study on the consumption of MX3 500mg capsule for knee discomfort not associated with injury.

The study showed that long term use of MX3 reduces knee joint discomfort, as indicated by Western Ontario and McMaster Universities Arthritis Index (Womac) and the McGill Pain Questionnaire.

MX3 products are developed and distributed by DMI and manufactured by the Northfield Laboratories Inc. MX3 products include MX3 500 mg capsule, MX3 Plus Capsule, MX3 Tea, and MX3 Coffee.

Published in the Sun.Star Davao newspaper on August 28, 2014.


DISCLAIMER: Sun.Star website welcomes friendly debate, but comments posted on this site do not necessary reflect the views of the Sun.Star management and its affiliates. Sun.Star reserves the right to delete, reproduce or modify comments posted here without notice. Posts that are inappropriate will automatically be deleted.

Forum rules: Do not use obscenity. Some words have been banned. Stick to the topic. Do not veer away from the discussion. Be coherent and respectful. Do not shout or use CAPITAL LETTERS!